TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07138833: A Multicenter, Open-label, Single Group, Phase 4 Study to Evaluate Dimethyl Fumarate Enteric-coated Capsules in Relapsing Multiple Sclerosis (RMS)

Sponsor: Qilu Pharmaceutical (Hainan) Co., Ltd. · Phase: PHASE4 · Area: CNS_NEUROLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,932,800

Rescue Site Savings

+$6,549,440

Unlock Full NCT07138833 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07138833 Rescue Dossier →